1. Market Research
  2. > Pharmaceutical
  3. > Pathology Market Trends
  4. > Diabetes, Metabolic Syndrome and Cardiovascular Disease

Diabetes, Metabolic Syndrome and Cardiovascular Disease

  • November 2014
  • -
  • TriMark Publications
  • -
  • 266 pages

There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease--sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes--the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world. To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i.e., Type 2) diabetes. This phenomenon is referred to as "metabolic syndrome" where a confluence of inflammatory conditions occur along with the diabetes. As a result, growing evidence appears to show that metabolic syndrome makes the diabetic patient susceptible to degenerative health conditions such as cardiovascular disease, stroke and, now believed, Alzheimer's disease. As the diabetes epidemic escalates, a new sense of urgency has taken hold.

Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization (WHO), as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed. This TriMark Publications report charts the changing landscape of the global diabetic population and explores the added health concerns resulting from the metabolic syndrome phenomenon and one of its major risk factors: cardiovascular disease (CVD). Furthermore, this study evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes and other inflammatory diseases in the future.

Table Of Contents

Diabetes, Metabolic Syndrome and Cardiovascular Disease










TABLE OF CONTENTS



1. Overview 11

1.1 Statement of Report 11

1.2 About this Report 11

1.3 Scope of the Report 12

1.4 Methodology 12

1.5 Executive Summary 14



2. Introduction 18

2.1 Demographics of Diabetes 19

2.1.1 Worldwide Diabetes 19

2.1.2 U.S. Diabetes 22

2.2 Economics of Diabetes 27

2.2.1 Worldwide Costs of Diabetes 27

2.2.2 Costs of Diabetes in the U.S. 28



3. Understanding the Metabolic Conditions Underlying and Associated with
Diabetes 33

3.1 Pre-Diabetes Syndrome 34

3.2 Metabolic Syndrome 34

3.2.1 Prevalence of Metabolic Syndrome 37

3.2.2 Management of Metabolic Syndrome 38

3.2.3 The Outlook for Metabolic Syndrome 38

3.2.4 The Debate Regarding Metabolic Syndrome 38

3.3 Diabetes and Inflammation 40

3.4 Diagnosis of Diabetes Mellitus 41

3.5 Progression of Diabetes 41

3.6 Risk Factors and Diabetes 41

3.6.1 Obesity 43

3.6.2 Stress-Induced Hyperglycemia 45

3.7 Complications and Co-Morbidities in Type 2 Diabetes 46

3.7.1 Preventing Complications and Co-Morbidities in Diabetes 50

3.7.2 Hypoglycemia Resulting from Treatment 52

3.8 Cardiovascular Disease (CVD) 52

3.8.1 CVD Facts 52

3.8.2 Cardiac Care Therapeutics 59

3.8.2.1 Anti-Hypertensive Drugs 61

3.8.2.2 Cholesterol Management Drugs 62

3.8.2.3 Anticoagulants 66

3.8.3 CVD Diagnostics 66



4. Pharmaceutical Industry and the Anti-Diabetes Market 68

4.1 The Worldwide Pharmaceutical Industry 68

4.1.1 Pharmaceutical Randamp;D Spending by Type, Growth Rate and Expenditure 68

4.1.2 Global Pharmaceutical Market 70

4.2 Total Diabetes Drug Market Size and Growth 76

4.2.1 Sales Forecast for the Global Anti-Diabetes Drug Market 80

4.3 Diabetic Medications Overview 82

4.3.1 Recent Trends in Diabetic Drug Usage 84

4.3.2 Market Influence Factors 86



5. Non-Insulin Anti-Diabetes Products 88

5.1 Anti-Diabetic Drug Therapy Overview 88

5.1.1 Sulfonylureas 91

5.1.2 Meglitinides 92

5.1.3 Biguanides 93

5.1.4 Thiazolidinediones (TZDs) 94

5.1.5 a-Glucosidase Inhibitors 96

5.1.6 Amylin Analog 97

5.1.7 Glucagon-like Peptide (GLP-1) Analogs and Agonists/Incretin Mimetics 97

5.1.7.1 Byetta (Exenatide) 98

5.1.7.2 Bydureon (Exenatide LAR) 99

5.1.7.3 Victoza (Liraglutide) 99

5.1.7.4 Tanzeum (Albiglutide) 99

5.1.7.5 Trulicity (Dulaglutide) 100

5.1.8 DPP-IV Inhibitors 100

5.1.8.1 Januvia (Sitagliptin) 101

5.1.8.2 Onglyza (Saxagliptin) 102

5.1.8.3 Tradjenta (Linagliptin) 102

5.1.8.4 Galvus (Vildagliptin) 102

5.1.8.5 Nesina (Alogliptin) 102

5.1.9 SGLT-2 Inhibitors 103

5.1.9.1 Invokana (Canagliflozin) 104

5.1.9.2 Farxiga (Dapagliflozin) 104

5.1.9.3 Jardiance (Empagliflozin) 105

5.1.9.4 Suglat (Ipragliflozin) 105

5.1.9.5 Lusefi (Luseogliflozin) 105

5.1.10 Combination Therapy 106

5.1.10.1 Antidiabetic Drug Options for Youth with Recent-Onset Type 2 Diabetes
Scarce 107

5.1.11 Comparisons of the Anti-Diabetes Drugs 107

5.2 Market Drivers and Trends 107

5.2.1 Market Share and Forecast of Non-Insulin Anti-Diabetic Drugs 108

5.3 Non-Insulin Anti-Diabetes Products in the Pipeline 110

5.3.1 Novel GLP-1 Agonists and Analogs 110

5.3.2 Novel DPP-IV Inhibitors 113

5.3.3 Sodium Glucose Cotransporter 2 (SGLT-2) Inhibitors 114

5.3.4 Emerging Anti-Diabetes Targets and Drugs in the Pipeline 115

5.3.4.1 Novel Approaches to Finding New Drug Targets 119



6. Insulin 120

6.1 Insulin Markets 120

6.1.1 Major Players and Market Share 122

6.1.2 Patent Expirations 124

6.1.3 Pathway for Insulin Biosimilars 124

6.1.3.1 Regulatory Avenues for Biosimilar Approval 124

6.1.3.2 Lantus Biosimilars 125

6.1.3.3 Key Issues for Insulin Biosimilars 125

6.1.4 Innovation Strategies 126

6.2 Insulin Therapeutics 126

6.2.1 Recommendations for Insulin Initiation and Administration 127

6.2.2 Short-Acting Insulin 130

6.2.3 Rapid-Acting Insulin 131

6.2.3.1 Fast-Acting Insulins in Development 132

6.2.4 Intermediate-Acting Insulin 133

6.2.5 Long-Acting Insulin 133

6.2.6 Insulin Mixtures 134

6.3 Pipeline Insulins in Development 135

6.3.1 Tresiba (Novo Nordisk) 135

6.3.2 Ryzodeg (Novo Nordisk) 135

6.3.3 Toujeo (Sanofi) 135

6.3.4 BIOD-531 (Biodel) 135

6.3.5 Xultophy (Novo Nordisk) 136

6.3.6 LixiLan (Sanofi) 136

6.3.7 rHUPH20 and Insulin (Halozyme) 136

6.3.8 FIAsp (Novo Nordisk) 136

6.3.9 BIOD-238, BIOD-250, and BIOD-351 (Biodel) 136

6.3.10 InsuPatch and InsuPad (Insuline Medical) 137

6.4 Non-Invasive Insulin Delivery 138

6.4.1 Inhaled Insulin 139

6.4.1.1 Afrezza 139

6.4.1.2 Dance Pharmaceuticals and Aerogen (Dance-501) 140

6.4.1.3 A Chronicle of Inhaled Insulins 141

6.4.2 Oral Insulin 142

6.4.3 Transdermal Insulin 145

6.5 Barriers for Non-Injected Insulin 146

6.6 Patient Potential for Non-Injected Insulin 147

6.7 Insulin Delivery Devices 147

6.7.1 Insulin Pens 149

6.7.2 Injections Aids 153

6.7.2.1 Automatic Injectors 154

6.7.2.2 Syringe Magnifiers 154

6.7.2.3 Injection Ports 155

6.7.3 Insulin Jet Injectors 155

6.7.4 Insulin Pumps 156

6.7.4.1 External Insulin Pumps 157

6.7.4.2 OneTouch Ping 159

6.7.4.3 Accu-Chek Combo Insulin Pump System 160

6.7.4.4 MiniMed Paradigm Real-Time Revel 160

6.7.4.5 MiniMed 530G with Enlite 161

6.7.4.6 Insulet Omnipod 161

6.7.4.7 DANA IIS 162

6.7.4.8 t:slim (Tandem Diabetes Care) 162

6.7.4.9 Snap (Asante) 162

6.7.4.10 Animas Vibe Pump/CGM 163

6.7.5 Insulin Infusion Sets 163

6.7.6 Insulin Patch Pumps in Development or Only Available Outside the U.S. 163

6.7.7 Implantable Insulin Pumps 166

6.7.8 Insulin Pump Market Share 166

6.7.9 Drivers of Demand for Pumps 168

6.8 Market Forecasts for Insulin Administration Technologies 168



7. Emerging Anti-Diabetes Technologies and Products 169

7.1 Projections for the Anti-Diabetes Drug Market 169

7.2 Artificial Pancreas 172

7.2.1 MiniMed 530G System 173

7.2.2 Animas Vibe System 174

7.2.3 Next Generation Medtronic Artificial Pancreas Systems 174

7.2.4 FDA's Artificial Pancreas Guidance Document 174

7.3 Insulin-Producing Cells 174

7.3.1 Gene Therapy 175

7.3.2 Cell Therapy Companies for Diabetes 176

7.3.2.1 ViaCyte (formerly Novocell, Inc.) 176

7.3.2.2 Sernova 177

7.4 Pancreatic Transplantation 177

7.4.1 Candidates for Pancreatic Transplantation 178

7.4.1.1 Pancreatic Organ Transplantation 178

7.4.1.2 Allo-Islet Transplantation 179

7.4.1.3 Implantation of Genetically Engineered b-Cells or Embryonic Stem Cells
179

7.4.2 ADA Position on Pancreatic Transplantation 179

7.5 Immune Modulators 180

7.6 Gastric Bypass Surgery to Treat Type 2 Diabetes 181

7.7 Anti-Obesity Drugs to Prevent or Delay Development of Type 2 Diabetes 181

7.7.1 Xenical (Roche) 181

7.7.2 Qsymia (Vivus) 181

7.7.3 Belviq (Arena Pharmaceuticals) 182

7.7.4 Contrave (Orexigen Therapeutics) 182

7.7.5 Anti-Obesity Drugs in Development 182

7.8 Other Anti-Diabetic Therapy Drug Candidates 182

7.8.1 Lipid Abnormalities 182

7.8.1.1 New Cholesterol Guidelines 183

7.8.2 High Blood Pressure 185

7.8.3 Aspirin Therapy 187

7.9 Drugs Used “Off-Label” 187

7.9.1 Warfarin Sodium 187

7.10 Insulin and Anti-Diabetes Drug Combinations 187

7.10.1 Xultophy (Novo Nordisk) 187

7.10.2 LixiLan (Sanofi) 188



8. Diagnosing Diabetes Using In Vitro Laboratory Tests 189

8.1 Diagnostic Guidelines 189

8.2 Diagnosis of Diabetes 189

8.2.1 Fasting Plasma Glucose (FPG) Test 192

8.2.2 Glucose Tolerance Test 193

8.2.3 Test for Glycosylated Hemoglobin (HbA1c or A1c) 193

8.2.4 Fructosamine 194

8.2.5 Screening Tests for Diabetes-Related Complications 195

8.3 Glucose Monitoring 196

8.3.1 Overview of Market Segment 198

8.3.2 Competitive Strategies 198

8.3.3 Analyses of the Current Market Conditions, Competition and Product Mix 200

8.3.3.1 First-Generation Monitors 201

8.3.3.2 Second-Generation Monitors 201

8.3.3.3 Third-Generation SMBG Technologies 202

8.3.3.4 Product Overview 202

8.3.3.4.1 LifeScan, Inc. 202

8.3.3.4.2 Roche Diagnostics 205

8.3.3.4.3 Bayer HealthCare 206

8.3.3.4.4 Abbott Diabetes Care 208

8.3.3.4.5 Other Players 210

8.3.4 What are the Advantages of Using a Continuous Glucose-Monitoring Device?
211

8.3.5 Minimally-Invasive Continuous Glucose Monitors in Development 212

8.3.6 Future of Non-Invasive Glucose Technology 212

8.3.7 Lancets and Lancing Devices 212



9. Market Trends, Challenges and Strategic Options 216

9.1 Overview 216

9.2 Diabetes Drug Market Trends 216

9.2.1 Overview 216

9.2.2 Emergence of Therapeutics with Improved Administration Characteristics 216

9.2.2.1 Barriers to the Initiation of Insulin Therapy in Type 2 Diabetics 218

9.2.3 Increasing Prevalence of Obesity 218

9.2.4 Consumer Preference Drives Product Development in Invasive Technology
Segment 219

9.3 Diabetes Mellitus Market Challenges 219

9.3.1 Overview 219

9.3.2 Patent Expirations 220

9.3.3 Market Prospects of Inhalable Insulin 220

9.4 Strategic Options 221

9.4.1 Developing Countries are Key Markets for Growth 222

9.4.2 Consumer-Driven Marketing Campaigns 223

9.4.3 Strategies for Successful New Product Launches 223

9.4.4 Collaborations and Strategic Alliances 224

9.5 FDA Guidelines for Developing Anti-Diabetic Drugs 224

9.6 Recent Industry Activity 225



10. Company Profiles 228

10.1 A. Menarini 228

10.2 Abbott Laboratories 228

10.3 Abbvie 232

10.4 Amgen 232

10.5 Amylin Pharmaceuticals (bought by Bristol-Myers Squibb) 233

10.6 Animas (part of Johnson andamp; Johnson) 233

10.7 Asante 233

10.8 Astellas Pharma, Inc. 233

10.9 AstraZeneca Plc 234

10.10 Bayer 235

10.11 Becton, Dickinson and Company 237

10.12 Biocon 238

10.13 Biodel 239

10.14 BodyMedia 239

10.15 Boehringer Ingelheim 239

10.16 Bristol Myers Squibb 240

10.17 Cellnovo 240

10.18 CeQur 240

10.19 ConjuChem 240

10.20 Daiichi Sankyo 241

10.21 Dance Biopharm 241

10.22 Debiotech 241

10.23 DexCom 241

10.24 Echo Therapeutics, Inc. 243

10.25 Eli Lilly 244

10.26 FIFTY50 Medical, Inc. 245

10.27 Flamel Technologies 245

10.28 Generex Biotechnology Corporation 245

10.29 GlaxoSmithKline Plc 245

10.30 Halozyme Therapeutics 246

10.31 Insulet 246

10.32 Insuline Medical Ltd. 247

10.33 Intarcia Therapeutics, Inc. 247

10.34 Janssen Research andamp; Development 247

10.35 Johnson andamp; Johnson 248

10.36 Kowa Pharmaceuticals 249

10.37 Lexicon Pharmaceuticals 249

10.38 MannKind Corporation 250

10.39 Medipacs 250

10.40 Medtronic 250

10.41 Merck andamp; Company, Inc. 251

10.42 Mitsubishi Tanabe Pharma Corporation 252

10.43 Novartis 252

10.44 Novo Nordisk 252

10.45 Oramed Pharmaceuticals 253

10.46 Orexigen Therapeutics, Inc. 253

10.47 Owen Mumford 254

10.48 PhaseBio Pharmaceuticals 254

10.49 Pfizer 254

10.50 Prometheon Pharma 255

10.51 Roche Diagnostics 255

10.52 Sanofi-Aventis 257

10.53 Sernova 258

10.54 Smiths Medical 258

10.55 SOOIL Development 259

10.56 Taisho Pharmaceuticals 259

10.57 Takeda 259

10.58 Tandem Diabetes Care, Inc. 259

10.59 Theracos, Inc. 260

10.60 Transdermal Specialties, Inc. 260

10.61 TransTech Pharma 260

10.62 Valeritas 260

10.63 Viacyte, Inc. (formerly Novocell) 261

10.64 Vivus, Inc. 261

10.65 Ypsomed Holding 261

10.66 Zealand Pharma A/S 261



Appendix 1: The History of Insulin 263





INDEX OF FIGURES



Figure 2.1: Worldwide Diabetes Cases, 2013 and 2035 19

Figure 2.2: Worldwide Prevalence of Diabetes (%) in Adults (20-79 Years), 2013
20

Figure 2.3: Annual Number of New Cases of Diagnosed Diabetes Among U.S. Adults
Aged 18-79 Years,

1980-2012 23

Figure 2.4: New Adult Cases of Diabetes Diagnosed in the U.S., 2012 24

Figure 2.5: Diagnosed and Undiagnosed Diabetes by Age in the U.S., 2013 24

Figure 2.6: Number of Deaths from Diabetes by Age in the U.S., 2010 26

Figure 2.7: Number of Diabetes Deaths by Race and Sex in the U.S., 2010 27

Figure 2.8: Mean Diabetes Healthcare-Related Expenditures Per Adult (20-79
Years) with Diabetes (USD),

2013 28

Figure 2.9: How Diabetes Dollars are Spent in the U.S., 2012 30

Figure 2.10: Percent of Medical Condition-Specific Expenditures Associated with
Diabetes, 2012 31

Figure 3.1: Maintenance of Normal Blood Sugar Levels 33

Figure 3.2: Prevalence of Self-Reported Obesity (BMI ³30) Among U.S. Adults,
2012 43

Figure 3.3: Prevalence of Obesity Among Adults in the U.S., 2009-2010 44

Figure 3.4: Percentage of Obese Children and Adolescents in the U.S., 2009-2010
44

Figure 3.5: Trends in Obesity Among Children and Adolescents in the U.S.,
1988-2010 45

Figure 3.6: Age-Adjusted Percentage of People with Diabetes Aged 35 Years or
Older Reporting Heart Disease or Stroke, by Sex, in the U.S., 1997-2011 46

Figure 3.7: Percentage of Adults with Diagnosed Diabetes Reporting Any Mobility
Limitation, by Age, in the U.S., 1997-2011 50

Figure 3.8: Number (in Millions) of Adults Aged 18 Years or Older with Diagnosed
Diabetes Reporting Visual Impairment, in the U.S., 1997-2011 50

Figure 3.9: Annual Death Rate of U.S. Population from Heart Disease, 1950-2009
54

Figure 3.10: Annual Death Rate of U.S. Population from Strokes, 1950-2009 55

Figure 3.11: Percentage Breakdown of Deaths Attributable to Cardiovascular
Disease in the U.S., 2010 55

Figure 3.12: Death Rates from Cardiovascular Disease by State, 2010 56

Figure 3.13: Percentage of Obese Adults in the U.S., 1960-2010 57

Figure 3.14: Percentage of Obese Children and Adolescents in the U.S., 1971-2010
58

Figure 3.15: Number of Annual Prescriptions for Popular Cholesterol Drugs,
2007-2012 63

Figure 4.1: Sales Forecast for the Global Diabetes Drug Market, 2010-2018 81

Figure 4.2: Sales Forecast for the U.S. Diabetes Drug Market, 2010-2018 82

Figure 4.3: Percentage of U.S. Diabetics Taking Medications, 2010-2012 83

Figure 4.4: U.S. Non-Insulin Anti-Diabetic Drug Prescriptions, 2013 85

Figure 5.1: Overview of GLP-1 and Blood Glucose 97

Figure 5.2: Overview of DPP-4 Inhibitors and Blood Glucose 101

Figure 5.3: SGLT-2 Inhibitor Mechanism of Action 103

Figure 5.4: Global Non-Insulin Anti-Diabetes Sales by Drug Class, 2013 108

Figure 5.5: Global Non-Insulin Anti-Diabetes Prescriptions by Drug Class, 2013
108

Figure 6.1: Global Sales of Lantus, 2005-2013 123

Figure 6.2: Insulin Pump Market Share, 2013 167





INDEX OF TABLES



Table 2.1: Regional Estimates of the Number of Diabetes (20-79 Years) in
Millions, 2013 and 2035 20

Table 2.2: Top Ten Countries with the Largest Estimated Number of Diabetics
(20-79 Years Age Group), \

2013 and 2035 21

Table 2.3: Worldwide Undiagnosed Diabetes in Adults (20-79 Years) by Region and
Income Group, 2013 21

Table 2.4: Countries with the Largest Number of Deaths Attributable to Diabetes,
2013 22

Table 2.5: U.S. Population of Diagnosed Diabetics Aged 20-79 Years, 2013 24

Table 2.6: Percentage of U.S. Adults with Diagnosed Diabetes by State, 2010 25

Table 2.7: Cost of Diagnosed Diabetes in the U.S., 2012 29

Table 2.8: Annual Cost of Care of United Healthcare Adult Members with Diabetes,
2009 30

Table 2.9: Healthcare Utilization by Diabetic Patients, 2012 31

Table 3.1: International Diabetes Federation (IDF) Diagnostic Criteria for
Metabolic Syndrome 35

Table 3.2: Ethnic Specific Values for Waist Circumference in IDF's Metabolic
Syndrome Criteria 35

Table 3.3: American Heart Association and National Heart, Lung, and Blood
Institute (AHA/NHLBI) Diagnostic Criteria for Metabolic Syndrome 35

Table 3.4: Additional Metabolic Criteria for Research 37

Table 3.5: Ten Leading Diagnoses for Co-Morbid Chronic Diseases in the U.S. 46

Table 3.6: Odds Ratio of Progression to Complications Associated with Type 2
Diabetes 48

Table 3.7: Prevalence of Complications Among Patients with Diabetes 49

Table 3.8: Novel Risk Factors and Possible Mechanisms of the Excess Risk of
Coronary Heart Disease in Type 2 Diabetes Mellitus 49

Table 3.9: Major Causes of End-Stage Renal Disease 49

Table 3.10: Clinical Recommendations for Adults with Diabetes 51

Table 3.11: Laboratory Assessment of Diabetic Vascular Disease 51

Table 3.12: Average Years Gained Free of Diabetes-Related Disease with Intensive
Management 52

Table 3.13: Summary of Cardiovascular Diseases (CVDs) 52

Table 3.14: Death Rate from Cardiovascular Diseases by Country, 2008 54

Table 3.15: Estimated Direct and Indirect Costs of Major Cardiovascular Diseases
and Stroke in the U.S.,

2010 58

Table 3.16: Selected Patent Expirations of Cardiac Care Drugs, 2012-2016 60

Table 3.17: Worldwide Market for Cardiac Care Therapeutics, 2010-2017 61

Table 4.1: Global Randamp;D Spending in the Pharmaceutical Industry, 2010-2014 68

Table 4.2: Pharmaceutical Companies Ranked by Total Randamp;D Expenditures, 2013 68

Table 4.3: Leading Therapy Classes for Randamp;D, 2014 69

Table 4.4: Leading Disease Indications for Randamp;D, 2014 70

Table 4.5: Cost of Clinical Trial Protocol Procedure by Endpoint Type, 2012 70

Table 4.6: Global Pharmaceutical Sales by Region and Country, 2012 and 2017, and
CAGR 2008-2012 and

2013-2017 71

Table 4.7: World Pharmaceutical Sales Share by Region, 2012 72

Table 4.8: Leading Ten Therapeutic Classes by U.S. Sales, 2009-2013 73

Table 4.9: Top Ten Therapeutic Classes by U.S. Dispensed Prescriptions,
2009-2013 73

Table 4.10: Estimated Leading Therapy Classes by Global Sales in the Developed
Market, 2017 73

Table 4.11: Estimated Leading Therapy Classes by Global Sales in the Pharmerging
Market, 2017 74

Table 4.12: Top Selling Drugs in the U.S., 2013 74

Table 4.13: Top Selling Drugs Worldwide, 2013 75

Table 4.14: Top Ten Global Pharmaceutical Companies by Global Sales, 2013 75

Table 4.15: Worldwide Anti-Diabetes (Insulin and Non-Insulin) Drug Market,
2010-2018 76

Table 4.16: U.S. Anti-Diabetes (Insulin and Non-Insulin) Drug Market, 2010-2018
76

Table 4.17: Anti-diabetic Therapy Markets, 2013 77

Table 4.18: The Leading Five Anti-Diabetics by Global Sales, 2013 80

Table 4.19: The Leading Five Anti-Diabetics by U.S. Sales, 2013 80

Table 4.20: Top Five Branded Anti-Diabetics by Prescription in the U.S., 2013 80

Table 4.21: American College of Physicians 2012 Practical Guideline for the Use
of Anti-Diabetes Drugs for Type 2 Diabetes 82

Table 4.22: Summary of Glucose-Lowering Interventions as Monotherapy 83

Table 5.1: Classes of Non-Insulin Hypoglycemic Agents 89

Table 5.2: Branded Non-Insulin Hypoglycemic Drugs Used to Treat Type 2 Diabetes
in the U.S., 2014 90

Table 5.3: Relative Efficacy of Diabetes Drugs 91

Table 5.4: Fixed-Dose Oral Anti-Diabetes Drug Combinations 106

Table 5.5: Worldwide Anti-Diabetes Non-Insulin Drug Market, 2010-2018 109

Table 5.6: U.S. Anti-Diabetes Non-Insulin Drug Market, 2010-2018 109

Table 5.7: GLP-1 Agonist Pipeline: Selected Drugs in Development 110

Table 5.8: DPP-IV Inhibitor Pipeline: Selected Drugs in Development 113

Table 5.9: SGLT-2 Inhibitor Pipeline: Selected Drugs in Development 115

Table 5.10: Fixed-Dose Combination Drugs with SGLT-2 Inhibitor: Selected Drugs
in Development 115

Table 5.11: Summary of Emerging Non-Insulin Anti-Diabetes Drug Categories 116

Table 6.1: Value Market Shares of Animal, Human and Modern Insulin, 1995-2013
120

Table 6.2: Worldwide Insulin Market, 2010-2018 121

Table 6.3: Worldwide Insulin Sales and Market Share by World Region, 2013 121

Table 6.4: U.S. Insulin Market, 2010-2018 121

Table 6.5: Key Drivers of the Type 2 Diabetes Insulin Market, 2013 122

Table 6.6: Worldwide Insulin Sales and Value Market Share by Company, 2013 122

Table 6.7: U.S. Insulin Sales and Value Market Share by Company, 2013 123

Table 6.8: Insulins on the U.S. Market 126

Table 6.9: Pharmacokinetics of Therapeutic Insulins on the U.S. Market 128

Table 6.10: Comparison of Recommendations from Existing Guidelines 130

Table 6.11: Pharmacokinetics of Short-Acting Insulins 130

Table 6.12: Pharmacokinetics of Rapid-Acting Insulins 131

Table 6.13: Pharmacokinetics of Intermediate-Acting Insulins 133

Table 6.14: Pharmacokinetics of Long-Acting Insulins 133

Table 6.15: Pharmacokinetics of Insulin Mixtures 134

Table 6.16: A Comparison of Existing Insulin Delivery Devices 148

Table 6.17: Insulin Pens 150

Table 6.18: Estimated Worldwide Demand for Insulin Pens by Volume, 2013-2018 152

Table 6.19: Injection Aids 153

Table 6.20: Jet Injectors 155

Table 6.21: Control Averages by Treatment 156

Table 6.22: Reduced Risk for Various Diseases When Blood Glucose is Near Normal
157

Table 6.23: Leading Insulin Pump Manufacturers 157

Table 6.24: Comparison of Current External Insulin Pumps on the Market 158

Table 6.25: Insulin Infusion Sets 163

Table 6.26: Worldwide Insulin Pump Market, 2013-2018 167

Table 7.1: Advantages and Disadvantages of Newer Type 2 Diabetes Therapies 172

Table 7.2: Cells of the Pancreas 175

Table 7.3: Statin Recommendations for Designated Treatment Groups 183

Table 7.4: Statins Currently Available in the U.S. 184

Table 7.5: Statin Intensity Chart 184

Table 7.6: Summary of Non-Statin Cholesterol Lowering Drugs 185

Table 7.7: Suggested Pharmacological Treatment Agents for Hypertension 186

Table 8.1: Criteria for the Diagnosis of Diabetes 190

Table 8.2: Categories of Increased Risk for Diabetes (Pre-Diabetes) 190

Table 8.3: Normal Glucose Values—Fasting State 190

Table 8.4: Criteria for Testing for Diabetes in Asymptomatic Adults 191

Table 8.5: Criteria for Type 2 Diabetes in Asymptomatic Children 191

Table 8.6: Screening for and Diagnosis of Gestational Diabetes Mellitus (GDM)
192

Table 8.7: Laboratory Assessment of Diabetic Vascular Disease 196

Table 8.8: Worldwide Glucose Self-Testing Market Sales (includes Meters, Strips
and Lancets),

2012-2018 197

Table 8.9: Market for Glucose Self-Testing in the U.S. (includes Meters, Strips
and Lancets), 2012-2018 197

Table 8.10: Market Share of U.S. Blood Glucose Self-Testing, 2013 198

Table 8.11: Lancet Characteristics 215

Table 9.1: BRIC countries, Percentage of GDP Spent on Healthcare, 2013 222

Table A1.1: Select Archived Press Release Excerpts 266






View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Artificial Pancreas - Pipeline Review, 2015

Artificial Pancreas - Pipeline Review, 2015

  • $ 4 000
  • Industry report
  • June 2015
  • by Global Data

Artificial Pancreas - Pipeline Review, 2015 Summary GlobalData's Medical Devices sector report, “Artificial Pancreas - Pipeline Review, 2015" provides an overview of Artificial Pancreas currently in ...

 Diabetes Drugs  Markets in China

Diabetes Drugs Markets in China

  • $ 4 000
  • Industry report
  • July 2015
  • by Asia Market Information & Development Company

China's demand for Diabetes Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth ...

Incretion Drugs Markets in China

Incretion Drugs Markets in China

  • $ 4 000
  • Industry report
  • August 2015
  • by Asia Market Information & Development Company

China's demand for Incretion Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.